Kynam Capital Management, LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Kynam Capital Management, LP disclosed 29 US equity positions worth $1.5bn in its Q4 2024 13F filing. The largest position was NTRA at 21.1% of the reported book, followed by PCVX and CLDX. Against the Q3 2024 filing, it opened 5 new positions, added to 13 and reduced 5 among the top 29 holdings.
What did Kynam Capital Management, LP own in Q4 2024? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | NTRA NATERA INC | Healthcare | 21.1% | $320.1m | 2,022,098 | -1% | reduced |
| 2 | PCVX VAXCYTE INC | Healthcare | 12.6% | $191.3m | 2,336,796 | 125% | added |
| 3 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 8.4% | $128.0m | 5,064,207 | 46% | added |
| 4 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 7.4% | $112.6m | 8,520,000 | 46% | added |
| 5 | DVAX DYNAVAX TECHNOLOGIES CORP | 5.5% | $83.8m | 6,560,835 | -21% | reduced | |
| 6 | CGON CG ONCOLOGY INC | Healthcare | 4.8% | $72.3m | 2,519,705 | 42% | added |
| 7 | COGT COGENT BIOSCIENCES INC | Healthcare | 4.7% | $71.0m | 9,105,000 | -1% | reduced |
| 8 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 4.5% | $68.3m | 9,085,368 | 0% | held |
| 9 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 4.2% | $63.8m | 3,326,262 | 32% | added |
| 10 | VERA VERA THERAPEUTICS INC | Healthcare | 4.1% | $61.7m | 1,457,910 | -8% | reduced |
| 11 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 4.0% | $60.6m | 4,899,497 | 0% | held |
| 12 | BEAM BEAM THERAPEUTICS INC | Healthcare | 2.9% | $43.6m | 1,756,158 | 35% | added |
| 13 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.4% | $36.2m | 1,225,576 | – | new |
| 14 | ENGENE HOLDINGS INC | 2.2% | $33.2m | 4,994,090 | 188% | added | |
| 15 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 2.1% | $31.4m | 1,802,750 | 31% | added |
| 16 | LQDA LIQUIDIA CORPORATION | Healthcare | 1.8% | $26.7m | 2,266,328 | 0% | held |
| 17 | IRWD IRONWOOD PHARMACEUTICALS INC | Healthcare | 1.4% | $20.8m | 4,685,563 | 27% | added |
| 18 | TSVT* 2SEVENTY BIO INC | 1.2% | $17.5m | 5,953,825 | 0% | held | |
| 19 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.0% | $15.3m | 1,252,738 | – | new |
| 20 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.0% | $15.1m | 390,792 | -14% | reduced |
| 21 | TYRA TYRA BIOSCIENCES INC | Healthcare | 0.5% | $7.4m | 530,478 | 13% | added |
| 22 | BNR BURNING ROCK BIOTECH LTD | 0.4% | $6.7m | 994,883 | 1% | added | |
| 23 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.4% | $6.7m | 3,641,447 | 76% | added |
| 24 | AMARIN CORP PLC | 0.4% | $6.0m | 12,414,628 | 0% | held | |
| 25 | PROQR THRAPEUTICS N V | 0.3% | $4.6m | 1,750,000 | – | new | |
| 26 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.3% | $4.1m | 1,000,000 | – | new |
| 27 | CRBU CARIBOU BIOSCIENCES INC | Healthcare | 0.3% | $3.8m | 2,406,147 | 2% | added |
| 28 | ACELYRIN INC | 0.2% | $2.7m | 847,366 | 0% | held | |
| 29 | CLYM CLIMB BIO INC | 0.1% | $984.6k | 547,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.